top of page

Aim 3

  1. Conduct analyses to inform clinical decision-making of blood, CSF, or PET testing in older adults living with MCCs, incorporating stakeholder input from providers, patients, and caregivers from the real-world cohorts.

  2. Provide guidance for how to disseminate and communicate blood biomarker results to patient populations.

  3. Develop models and estimates to inform Medicare and other insurance coverage for ADRD biomarkers in real world populations.

bottom of page